share_log

Acrivon Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Sands Capital Life Sciences Pulse Fund II, L.P.(7.4%),Sands Capital Ventures, LLC(7.4%), etc.

SEC announcement ·  Feb 13 15:45
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more